



CNMV  
Markets Directorate General  
C/ Edison núm. 4  
28006 Madrid

Madrid, March 23, 2026

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

#### **OTHER RELEVANT INFORMATION**

Pharma Mar, S.A. announces that its treatment Zepzelca® (lurbinectedin), in combination with atezolizumab (Tecentriq®), has been approved by the Taiwan Food and Drug Administration (TFDA) as a first-line maintenance treatment for adult patients with advanced small cell lung cancer (SCLC).

Please find attached press release that Pharma Mar, S.A. will distribute to the media.

**Pharma Mar S.A.**  
**Avda. de los Reyes, 1**  
**P.I. La Mina**  
**28770 Colmenar Viejo**  
**(Madrid) Spain**  
**[www.pharmamar.com](http://www.pharmamar.com)**

# PharmaMar's treatment for small cell lung cancer approved as first-line maintenance therapy in Taiwan



- In addition to Taiwan, Zepzelca<sup>®</sup> (lurbinectedin) in combination with immunotherapy has also recently been approved for the same indication in the United Arab Emirates, Israel, Uruguay, Oman, Ecuador, Paraguay and Peru, totalling 10 countries including USA and Switzerland
- This adds to the 22 approvals that the Spanish company's compound has obtained worldwide as a second-line monotherapy.

**Madrid, March 23<sup>rd</sup>, 2026.-** PharmaMar (MSE:PHM) a Spanish biopharmaceutical company with 40 years of experience, announced today that its treatment Zepzelca<sup>®</sup> (lurbinectedin), in combination with atezolizumab (Tecentriq<sup>®</sup>), has been approved by the Taiwan Food and Drug Administration (TFDA) as a first-line maintenance treatment for adult patients with advanced small cell lung cancer (SCLC).

This approval as a first-line maintenance therapy means that the drug is administered after the initial induction treatment for those patients who achieve stable disease or better, in order to maintain the response achieved. In addition to Taiwan, this first-line maintenance combination has recently been approved for the same indication in the United Arab Emirates, Oman, Israel, Uruguay, Ecuador, Paraguay and Peru joining the United States and Switzerland, the first countries to have approved it for this indication. The Marketing Authorization Application (MAA) is currently under review by the European Medicines Agency (EMA), as well as in other countries worldwide.

PharmaMar commercializes its products outside Europe through agreements with strategic partners, with the aim of facilitating patient access worldwide to its innovative oncology therapies. Specifically, the Company collaborates with Lotus Pharmaceutical in Taiwan; Immedica in Oman and the United Arab Emirates; in

Israel with Megapharm and Adium Pharma in Uruguay, Paraguay, Peru and Ecuador.

Furthermore, lurbinectedin as a monotherapy is approved as a second-line treatment, that is, after disease progression during or following platinum-based chemotherapy, in 22 countries.

Small cell lung cancer accounts for about 15% of lung cancer cases and is characterized by its aggressive behavior, and an early tendency to spread<sup>i,ii</sup>.

#### **Legal warning**

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

#### **About PharmaMar**

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself. In addition, Zepzelca® (lurbinectedin), in the US and other countries; and Aplidin® (plitidepsin), in Australia, each with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: PM534 and PM54.

Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi) and contract-manufacturing (CDMO) of oligonucleotides. For more information, please visit: [www.pharmamar.com](http://www.pharmamar.com).

#### **About Zepzelca®**

Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinascidia turbinata. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Tecentriq (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.

### **About the IMforte Phase 3 Trial**

The Phase 3 global IMforte trial evaluated lurbinectedin plus atezolizumab as a first-line maintenance therapy in patients with ES-SCLC. 483 patients were randomized after completion of 4 cycles of induction therapy with atezolizumab plus carboplatin and etoposide. From the point of randomization, the median OS for the lurbinectedin plus atezolizumab regimen was 13.2 months versus 10.6 months for atezolizumab alone (stratified hazard ratio [HR] = 0.73; 95% CI: 0.57–0.95; p = 0.0174). From the point of randomization, the median PFS by independent assessment was 5.4 months versus 2.1 months, respectively (stratified HR = 0.54, 95% CI: 0.43–0.67; p < 0.0001). Treatment duration for patients in the lurbinectedin plus atezolizumab arm was twice as long as the atezolizumab arm, with a median maintenance treatment duration of 4.2 months versus 2.1 months, respectively.

The lurbinectedin plus atezolizumab combination as maintenance therapy was generally well tolerated with no new safety signals identified. In the lurbinectedin plus atezolizumab and atezolizumab arms, respectively, treatment-related adverse events (TRAEs) occurred in 83.5% versus 40.0% of patients, with Grade 3–4 TRAEs in 25.6% versus 5.8% and Grade 5 TRAEs in 0.8% (two patients with sepsis and febrile neutropenia) versus 0.4% (one patient with sepsis). AEs led to treatment discontinuation in 6.2% of patients in the lurbinectedin plus atezolizumab arm and 3.3% of patients in the atezolizumab arm.

### **Media Contact:**

Lara Vadillo – Communications director lvadillo@pharmamar.com

Miriam Collados Gordo – Corporate Communications Manager mcollados@pharmamar.com

Phone: +34 918466000

### **Capital Markets & Investor Relations:**

José Luis Moreno – VP Capital Markets & Investor Relations

Natalia Amo – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)

---

<sup>i</sup> General information on small cell lung cancer. [Small Cell Lung Cancer Treatment \(PDQ®\) - NCI](#)

<sup>ii</sup> [Lung Cancer Statistics | How Common Is Lung Cancer? | American Cancer Society](#)